Correspondence on 'Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial'

Ann Rheum Dis. 2023 Mar;82(3):e67. doi: 10.1136/annrheumdis-2020-219666. Epub 2021 Jan 27.

Authors

Bin Wang^#¹, Shiju Chen^#¹, Jingxiu Xuan^#¹, Yan Li¹, Qing Zheng¹, Xinwei Zhang¹, Yuan Liu², Guixiu Shi^{2

3}

Affiliations

¹ Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
² Department of Rheumatology and Clinical Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, China gshi@xmu.edu.cn liuyuan@xmu.edu.cn.
³ Department of Science & Technology, Xiamen Key Laboratory of Rheumatology and Clinical Immunology, Xiamen, China.

^# Contributed equally.

PMID: 33504477
DOI: 10.1136/annrheumdis-2020-219666

No abstract available

Keywords: biological therapy; sjogren's syndrome; therapeutics.

Publication types

Letter
Comment

MeSH terms

Humans
Multicenter Studies as Topic
Randomized Controlled Trials as Topic
Receptors, Interleukin-6
Sjogren's Syndrome* / drug therapy
Treatment Outcome

Substances

Receptors, Interleukin-6